WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

PATENTSCOPE

MARKUSH SEARCH, PATENT FAMILIES AND RELATED FEATURES

Magdalena Zelenkovska, Senior Patent Data Manager
Patent Database Section, Global Databases Division
Infrastucture and Platforms Sector

Geneva, November 23, 2021

Agenda

- Coverage
- NPL
- Deep Linking
- PATENTSCOPE Patent Families Definition
- PATENTSCOPE Patent Familes vs. DocDB Patent Families
- Markush Search

PATENTSCOPE COVERAGE NEWS

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

Coverage News

- Collections published in 2021: New Zealand, Finland, Estonian Full text, Kazakhstan and Poland
- Improved Coverage page:
  - Latest Biblio
  - Update Frequency
  - Chemical Data
  - Chemical Indexed

https://patentscope.wipo.int/search/en/help/data_coverage.jsf

- Coming soon: Austria, Norway and Switzerland

NATIONAL COLLECTIONS - DATA COVERAGE

Offices for which PCT national phase information is available

Updated: October 14, 2021

Country	Latest Biblio	Update Frequency	Biblio Data	Abstract	Chemical Data	Chemical indexed	Doc images	OCR (full-text) Indexed	Nb records
PCT	14.10.2021	Daily	19.10.1978 - 14.10.2021	19.10.1978 - 14.10.2021	11.01.1979 - 07.10.2021	860,272	4,162,545	**Total: 4,154,561** English: 2,358,013 French: 138,461 Spanish: 28,271 German: 411,397 Korean: 133,068 Japanese: 696,480 Chinese: 362,074 Russian: 21,324 Portuguese: 5,473	4,162,545

Non-Patent Literature in Patentscope

- Patent and non-patent literature can be searched and consulted in the same way
- More than 175k documents (biblio and full-text) available and indexed
  - Open access (OA) content on Nature.com
  - Wikipedia
  - More NPL sources will follow
- All documents have been classified, using AI, under the IPC classification
- Full-text available in English and can be translated into other 11 other languages with the help of WIPO Translate

MIR100HG RNA

57 results Offices all Languages en Stemming false Single Family Member false Include NPL true

Sort: Relevance Per page: 10 View: All 1 / 6

Machine translation

1. **107858434** APPLICATION OF LNCRNA IN DIAGNOSIS AND PROGNOSTIC PREDICTION OF LIVER CANCER CN - 30.03.2018

Int.Class C12Q 1/6886 Appl.No 201711414821.X Applicant FUDAN UNIVERSITY SHANGHAI CANCER CENTER Inventor WANG YILIN

The invention discloses application of lncRNA in diagnosis and prognostic prediction of liver cancer. The lncRNA is selected from one or multiple of TD-2574D22.4, SERHL, MIR100HG and SNHG20, and experiments prove that lncRNA TD-2574D22.4, SERHL, MIR100HG and SNHG20 present differential expression in patients with liver cancer. The invention further discloses a risk scoring model for predicting prognosis of the liver cancer. The risk scoring model serves as an auxiliary means to predict prognosis of the patients with the liver cancer so as to perform risk evaluation and monitoring on the patients.

2. **10.1038/S41388-021-01803-8** THE NONCODING *MIR100HG* RNA ENHANCES THE AUTOCRINE FUNCTION OF TRANSFORMING GROWTH FACTOR Β SIGNALING NPL - 01.05.2021

Int.Class C12N 15/113 Publisher nature Journal Oncogene

Abstract Activation of the transforming growth factor β [TGFβ] pathway modulates the expression of genes involved in cell growth arrest, motility, and embryogenesis. An expression screen for long noncoding RNAs indicated that TGFβ induced mir-100-let-7a-2-mir-125b-1 cluster host gene [MIR100HG] expression in diverse cancer types, thus confirming an earlier demonstration of TGFβ-mediated transcriptional induction of MIR100HG in pancreatic adenocarcinoma. MIR100HG depletion attenuated TGFβ signaling, expression of TGFβ-target genes, and TGFβ-mediated cell cycle arrest. Moreover, MIR100HG silencing inhibited both normal and cancer cell motility and enhanced the cytotoxicity of cytostatic drugs. MIR100HG overexpression had an inverse impact on TGFβ signaling responses. Screening for downstream effectors of MIR100HG identified the ligand TGFβ1. MIR100HG and TGFB1 mRNA formed ribonucleoprotein complexes with the RNA-binding protein HuR, promoting TGFβ1 cytokine secretion. In addition, TGFβ regulated let-7a-2–3p, miR-125b-5p, and miR-125b-1–3p expression, all encoded by MIR100HG intron-3. Certain intron-3 miRNAs may be involved in TGFβ/SMAD-mediated responses [let-7a-2–3p] and others [miR-100, miR-125b] in resistance to cytotoxic drugs mediated by MIR100HG. In support of a model whereby TGFβ induces MIR100HG, which then enhances TGFβ1 secretion, analysis of human carcinomas showed that MIR100HG expression correlated with expression of TGFB1 and its downstream extracellular target TGFBI. Thus, MIR100HG controls the magnitude of TGFβ signaling via TGFβ1 autoinduction and secretion in carcinomas.

3. **10.1038/S41419-018-0869-2** LNCRNA MIR100HG PROMOTES CELL PROLIFERATION IN TRIPLE-NEGATIVE BREAST CANCER NPL - 24.07.2018

DEEP LINKING

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

Deep Linking - Coverage

- Deep Linking enabled for 32 authorities:
  - Australia
  - Canada
  - Czech Republic
  - Germany
  - Denmark
  - Dominican Republic
  - Euro-Asian Patent Office
  - Egypt
  - European Patent Office
  - Spain
  - Finland
  - France
  - Great Britain
  - Georgia
  - Greece
  - Israel
  - South Korea
  - Kazakhstan
  - Latvia
  - Lithuania
  - Morocco
  - Mexico
  - Netherlands
  - Panama
  - Philippines
  - Poland
  - Portugal
  - Russia
  - Saudi Arabia
  - Sweden
  - Slovakia
  - United States

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

Deep Linking - Access

PATENTSCOPE

Office
Republic of Korea

Application Number
1020180013779

Application Date
05.02.2018

Publication Number
1020190094520

Publication Date
14.08.2019

Grant Number
102139528

Grant Date
30.07.2020

Publication Kind
B1

IPC
C08F 36/04 | C08F 2/00 | C08F 2/01 | C08F 4/48 | C08F 4/52 | C08F 4/619
View more classifications

CPC
C08F 36/04 | C08F 2/001 | C08F 2/01 | C08F 4/48 | C08F 4/52 | C08F 4/619
View more classifications

Applicants
주식회사 엘지화학
LG CHEM, LTD.

Inventors
KO JUN SEOK
JEONG HOI IN
HWANG WOO SUNG
고준석
KIM DONG MIN
정희인
LEE JEONG SEOK
황우성
김동민

Title
[EN] METHOD FOR MANUFACTURING CONJUGATED DIENE-BASED POLYMER AND APPARATUS FOR MANUFACTURING CONJUGATED DIENE-BASED POLYMER
[KO] 공액디엔계 중합체 제조방법 및 공액디엔계 중합체 제조장치



Abstract
[EN]
The present invention relates to a method for manufacturing a conjugated diene-based polymer. More specifically, the present invention provides the method for manufacturing the conjugated diene-based polymer and an apparatus for manufacturing the conjugated diene-based polymer, wherein the method comprises steps of: manufacturing a first polymer solution comprising a first conjugated diene-based polymer by adding a conjugated diene-based monomer, a catalyst, and a solvent to a parallel polymerization reactor in which two or more polymerization reactors are connected in parallel and performing a polymerization reaction; and manufacturing a second polymer solution comprising a second conjugated diene-based polymer by introducing the first polymer solution discharged from the parallel polymerization reactor into a series polymerization reactor connected in series with the parallel polymerization reactor and performing the polymerization reaction. During the polymerization reaction of the series polymerization reactor, gas generated by polymerization heat is condensed by a condenser provided in the series polymerization reactor and refluxed to a parallel polymerization reactor, and a reaction temperature of the series polymerization reactor is maintained at least 10 deg;C lower than the reaction temperature of the parallel polymerization reactor. COPYRIGHT KIPO 2019

[KO]
본 발명은 공액디엔계 중합체 제조방법에 관한 것으로, 보다 상세하게는 2개 이상의 중합 반응기가 병렬로 연결된 병렬 중합 반응기에, 공액디엔계 단량체, 촉매 및 용매를 투입하고 중합 반응을 수행하여 제1 공액디엔계 중합체를 포함하는 제1 중합체 용액을 제조하는 단계; 및 상기 병렬 중합 반응기로부터 배출된 제1 중합체 용액을, 병렬 중합 반응기와 직렬로 연결된 직렬 중합 반응기에 투입하고 중합 반응을 수행하여 제2 공액디엔계 중합체를 포함하는 제2 중합체 용액을 제조하는 단계를 포함하고, 상기 직렬 중합 반응기의 중합 반응 시, 중합열에 의해 발생되는 기체는, 직렬 중합 반응기에 구비된 콘덴서에 의해 응축되어 병렬 중합 반응기로 환류되며, 상기 직렬 중합 반응기의 반응온도는, 병렬 중합 반응기의 반응온도 보다 10 ℃ 이상 낮게 유지되는 것인 공액디엔계 중합체 제조방법 및 이를 실시하기 위한 공액디엔계 중합체 제조장치를 제공한다.

Related patent documents
CN110869398 EP3636679 US20200207888 JP2020526625 WO/2019/151672

IP Office

METHOD FOR PREPARING CONJUGATED DIENE BASED POLYMER AND APPARATUS FOR PREPARING CONJUGATED DIENE BASED POLYMER
공액디엔계 중합체 제조방법 및 공액디엔계 중합체 제조장치

Details | Unexam. Full Text | Publ. Full Text | Registr. Details | Administrative

Details | Biographical Information | Legal Status | Claim | Designated States | Citation | Family Patent

(51) Int. CL	C08F 36/04(2006.01.01) C08F 2/01(2006.01.01) C08F 2/00(2006.01.01) C08F 4/52(2006.01.01) C08F 4/619(2006.01.01) C08F 4/639(2006.01.01) C08F 4/48(2006.01.01)
(52) CPC	C08F 36/04(2013.01) C08F 2/01(2013.01) C08F 2/001(2013.01) C08F 4/52(2013.01) C08F 4/619(2013.01) C08F 4/639(2013.01) C08F 4/48(2013.01)
(21) Application No.(Date)	1020180013779 (2018.02.05)
(71) Applicant	LG CHEM, LTD.
(11) Registration No.(Date)	1021395280000 (2020.07.24)
(65) Unex. Pub. No.(Date)	1020190094520 (2019.08.14) Full-doc Down
(11) Publication No.(Date)	(2020.07.30) Full-doc Down
(86) Int'l Application No.(Date)	
(87) Int'l Unex. Pub. No.(Date)	
(30) Priority info. (Country / No. / Date)	
Legal Status	Registered
Examination Status	Decision to grant (General)
Trial Info	
Kind	Domestic Application / New Application
Right of Org. Application No. (Date)	
Related Application No.	
Request for an examination(Date)	Y(2019.05.28)
Number of examination claims	9

Download | Zoom



DOI | DOI Copy
QR | QR Download

KPA (Korea Patent Abstract) The present invention relates to a method for manufacturing a conjugated diene-based polymer. More specifically, the present invention provides the method for manufacturing the conjugated diene-based polymer and an apparatus for manufacturing the conjugated diene-based polymer, wherein the method comprises steps of: manufacturing a first polymer solution comprising a first conjugated diene-based polymer by adding a conjugated diene-based monomer, a catalyst, and a solvent to a parallel polymerization reactor in which two or more polymerization reactors are connected in parallel and performing a polymerization reaction; and manufacturing a second polymer solution comprising a second conjugated diene-based polymer by introducing the first polymer

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

Deep Linking – Access to Additional Information

Citations

METHOD FOR PREPARING CONJUGATED DIENE BASED POLYMER AND APPARATUS FOR PREPARING CONJUGATED DIENE BASED POLYMER
공액디엔계 중합체 제조방법 및 공액디엔계 중합체 제조장치

Details | Unexam. Full Text | Publ. Full Text | Registr. Details | Administrative

Details | Biographical Information | Legal Status | Claim | Designated States | Citation | Family Patent

※ The information is based on the citation information attached to a Notification of reason for refusal by the examiner.

▸ Forward Citation

Country	Pub. Date	Pub. No	Title	IPC
Republic of Korea	1020170047031 A	2017.05.04	APPARATUS FOR PREPARING OF POLYBUTADIENE	C08F 2/01

▸ Backward Citation

Application No	Application Date	Title	IPC
:: Empty ::			

Other Patent Families

METHOD FOR PREPARING CONJUGATED DIENE BASED POLYMER AND APPARATUS FOR PREPARING CONJUGATED DIENE BASED POLYMER
공액디엔계 중합체 제조방법 및 공액디엔계 중합체 제조장치

Details | Unexam. Full Text | Publ. Full Text | Registr. Details | Administrative

Details | Biographical Information | Legal Status | Claim | Designated States | Citation | Family Patent

No.	Family No.	Country(code)	Country	Type
1	CN110869398	CN	China	A
2	EP03636679	EP	European Patent Office (EPO)	A1
3	EP03636679	EP	European Patent Office (EPO)	B1
4	JP32526625	JP	Japan	A
5	JP06929432	JP	Japan	B2
6	US20200207888	US	United States of America	A1
7	WO2019151672	WO	World Intellectual Property Organization (WIPO) (International Bureau of)	A1

▸ DOCDB Family info.

No.	Family No.	Country(code)	Country	Type
1	CN110869398	CN	China	A
2	EP3636679	EP	European Patent Office (EPO)	A1
3	EP3636679	EP	European Patent Office (EPO)	A4

Legal Status

METHOD FOR PREPARING CONJUGATED DIENE BASED POLYMER AND APPARATUS FOR PREPARING CONJUGATED DIENE BASED POLYI
공액디엔계 중합체 제조방법 및 공액디엔계 중합체 제조장치

Details | Unexam. Full Text | Publ. Full Text | Registr. Details | Administrative

Details | Biographical Information | Legal Status | Claim | Designated States | Citation | Family Patent

No.	Document Title(Eng.)	Receipt/Delivery Date	Status	Receipt/Delivery No.
1	[Patent Application] Patent Application ([특허출원]특허출원서)	2018.02.05	수리 (Accepted)	112018012322823
2	Notification of change of applicant's information (출원인정보변경(경정)신고서)	2018.11.12	수리 (Accepted)	412018522760480
3	Notification of change of applicant's information (출원인정보변경(경정)신고서)	2018.12.19	수리 (Accepted)	412018526181830
4	[Request for Examination] Request for Examination (Request for Preferential Examination) ([심사청구]심사청구(우선심사신청)서)	2019.05.28	수리 (Accepted)	112019054435612
5	Notification of change of applicant's information (출원인정보변경(경정)신고서)	2019.08.19	수리 (Accepted)	412019516428496
6	Notification of reason for refusal (의견제출통지서)	2020.05.15	발송처리완료 (Completion of Transmission)	952020033641319
7	[Amendment to Description, etc.] Amendment ([명세서등 보정]보정서)	2020.06.10	보정승인간주 (Regarded as an acceptance of amendment)	112020059593726
8	([거절이유 등 통지에 따른 의견]의견서·답변서·소명서)	2020.06.10	수리 (Accepted)	112020059591915
9	Decision to grant (등록결정서)	2020.07.17	발송처리완료 (Completion of Transmission)	952020048764300

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION



PATENT FAMILIES

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

PATENTSCOPE Patent Families Definition

- Groups of unique filings → Families of filings
  - 99.5 million filings translates into 124,5 million publications



PATENTSCOPE Patent Families Definition

Timeline



Scope

PCT Patent Families

- Built on strong links between a PCT application and it national entries
- A combination of
  - national phase entry data as received by participating offices
  - prior PCT links in the bibliographic data
  - first and only priority included

PCT Patent Families enriched with US related documents

- Provisionals, re-issues, republications, divisionals, continuations and continuations in part considered
- Grouping based on the calculation of first parent
- all re-issues, republications, divisionals and continuations of an application and the application itself grouped in a single family. The continuations in part are not included in that family

PATENTSCOPE Patent Families

- Include families via both PCT and Paris route
- based on priority data

Enriched PATENTSCOPE Patent Families

- Considers IP office specific practices
  - DPMA – Divisionals
  - NZ - Divisionals, Provisional
  - EG - Divisionals
  - JPO – Divisionals
  - PL – Divisionals
  - EP national entries from ES, DK, PT, LT and PL

PATENTSCOPE Patent Families – Inclusion Criteria

Inclusion Criteria	
	IC1 - PCT application from which the family originated
	IC2 - National entry of a PCT application
	IC3 - National entry of a PCT application not found in PATENTSCOPE
	IC4 - US application related to another US application already included in the family
	IC5 - Sole priority inside the family
	IC6 – Connected by priority field
	IC7 -National application related to another application of the same national office already included in the family

PATENTSCOPE Patent Families – Inclusion Criteria (first Release)

- PCT application → IC1
- PCT NPE
  - NPE found in Patentscope → IC2
  - NPE not found in Patentscope → IC3
  - NPE does not meet the requirements
- National Prior PCT → IC2
- PCT priorities, sole priority → IC5

Office	Entry Date	National Number	National Status
Iran [Islamic Republic of]	20.01.2020	139850140003009756	
India	01.05.2020	202047018695	Published: 12.06.2020
India		2.02047E+11	Published: 12.06.2020

PATENTSCOPE Patent Families – Inclusion Criteria (second Release)

- Treated separately because of complexity
- Consider
  - Provisional applications for future referencing
  - Republications & Reissue → IC4
  - Continuations & Divisionals → IC4, defined as pairs of a parent and a child and attached to an application in a recursive manner
  - Continuations-in-part, not part of the same family

PATENTSCOPE Patent Families – Inclusion Criteria (second Release) - Example

Enrichment via US related documents – An example



10732326 - priorities=related documents

11367134 - priorities=related documents + application itself

12023431 - no priorities

12023416 - priorities=related documents + application itself

13247241 - no priorities

14601340 - no priorities

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

PATENTSCOPE Patent Families – Inclusion Criteria (third Release)

- Consider
  - Sole priority (PCT or national) → IC5
  - Matching priorities (PCT and national) → IC6
- Exceptions
  - US Provisional
  - JP Withdrawn
  - Circular priorities

PATENTSCOPE Patent Families – Inclusion Criteria (third Release) - Example

J-PlatPat
Japan Platform for Patent Information

Inquiry of history information

PatentsApplication 2015-171932 Publication2017-049761

Register6367166 Right has not been cancelled

* NOTICES *

JPO and INPIT are not responsible for any damages caused by the use of this translation.

1.This document has been translated by computer. So the translation may not reflect the original precisely.

2.**** shows the word which can not be translated.

History Records | Application Information | Registration Information | Divisional Application Informatio

Patents
Application 2015-171932
Register 6367166

1

Application 2018-126562

2

Application 2018-147687 | Application 2019-124457 | Application 2019-124458



JP2017049761 ELECTRONIC APPARATUS AND METHOD 01.09.2015
Appl.No 2015171932 Applicant TOSHIBA CORP Pub.Date 09.03.2017 Pub.Kind A,B2 Pub.Lang ja IC5

US20170061758 ELECTRONIC APPARATUS AND METHOD 14.12.2015
Appl.No 14968759 Applicant KABUSHIKI KAISHA TOSHIBA Pub.Date 02.03.2017 Pub.Kind A1,B2 Pub.Lang IC4

JP2018195321 WEARABLE TERMINAL AND METHOD 03.01.2018
Appl.No 2018126562 Applicant TOSHIBA CORP Pub.Date 08.12.2018 Pub.Kind A Pub.Lang ja IC7

JP2018190460 WEARABLE TERMINAL AND METHOD 06.08.2018
Appl.No 2018147687 Applicant TOSHIBA CORP Pub.Date 29.11.2018 Pub.Kind A Pub.Lang ja IC7

US20190172334 ELECTRONIC APPARATUS AND METHOD 01.02.2019
Appl.No 16265900 Applicant KABUSHIKI KAISHA TOSHIBA Pub.Date 06.06.2019 Pub.Kind A1,B2 Pub.Lang IC4

JP2019197564 WEARABLE TERMINAL, SYSTEM, AND METHOD 03.07.2019
Appl.No 2019124457 Applicant TOSHIBA CORP Pub.Date 14.11.2019 Pub.Kind A Pub.Lang ja IC7

JP2019197565 WEARABLE TERMINAL, SYSTEM, AND METHOD 03.07.2019
Appl.No 2019124458 Applicant TOSHIBA CORP Pub.Date 14.11.2019 Pub.Kind A Pub.Lang ja IC7

PATENTSCOPE Patent Families – Inclusion Criteria (continuous enrichment)

US Application with PL priority in PATENTSCOPE



The PL priority and its divisionals in the patent search tool of the Polish Patent Office



WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

PATENTSCOPE Patent Families - Interface





WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION


DocDB Patent Families
Europäisches Patentamt
European Patent Office
Office européen des brevets
VS
WIPO
WORLD INTELLECTUAL PROPERTY ORGANIZATION
PATENTSCOPE Patent Families

PATENTSCOPE vs. DOCDB Patent families

- Comparing PATENTSCOPE patent families to DocDB families is necessary because DocDB patent families have been the most widely accepted patent families by the user community

- **Disclaimer:** The numbers in the slides below are based on unique filings. In DocDB multiple versions of the same filing exist while in PATENTSCOPE they are aggregated in one record. For the purposes of this comparison the counts shown for DocDB are also aggregated values. It is possible that due to formatting issues and in exceptional cases some filings are being counted more than once. Therefore the numbers below should be read as closest approximation rather than exact numbers. In order to do this comparison with grater certainty the numbers calculated should be provided by each authority for its own data.

PATENTSCOPE vs. DOCDB Patent families* - coverage differences



PATENTSCOPE

- 100 million distinct filings
- 99 million present in PATENTSCOPE and an additional 1 million national entries not found in PATENTSCOPE

ESPACENET

- 104.7 million distinct filings
- At the top of the list of authorities not present in PATENTSCOPE is Taiwan with 1,5 million distinct filings, Austria with 1 million and Switzerland with 0,7 million filings



This doesn't mean that differences in the coverage counts are due to the missing authorities! On the contrary the coverage differences come in many flavours!

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

PATENTSCOPE vs. DOCDB Patent families* - coverage differences



WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

PATENTSCOPE vs. DOCDB Patent families - coverage differences

MATCHING COVERAGE

- Majority of IP offices including:IP5, Latipat, Arabpat Australia, Russia, Canada

EPO MEMBER STATES

- Matching coverage in most major collections such as France, Germany, Great Britain, Denmark, Finland etc..
- Lack of a few additional collections compensated with National Entries

PATENTSCOPE'S STRENGHTS

- National Collections from Southeast Asian Countries and India
- National entry phase from Iran, Angola, Sri Lanka etc..

LACK OF DATA ON BOTH SIDES

- ARIPO member states

The lists above are only random examples and are not exhaustive!

PATENTSCOPE vs. DOCDB Patent families* - the counts!

		PATENTSCOPE	DocDB
Unique filings		100 million	104.7 million
Number of patent family ids		71.5 million	75 million
Multi-member families	Total	**8.93 million**	**8.98 million**
	Number of distinct filings in family	**37.3 million**	**37.8 million**
Single-member families	With members published more than once	9.5 million	11.9 million
	With members published only once	53 million	54.1 million
	Total	62.5 million	66 million

* (on 19.11.2021)

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

PATENTSCOPE vs. DOCDB Patent families – the case of being complementary…

PATENTSCOPE only	PATENTSCOPE & Espacenet	Espacenet Only
• **ID**2016/04223 • **IN**2435/KOLNP/2015 • **MY**PI 2015001901 • **TH**171317 • **VN**45030 • **VN**1201503122	• AR094676A1 • AU2014211583A1/AU2014211583B2 • CA2899013A1/CA2899013C • CN105229736A/CN105229736B • CN110517700A • EP2951820A1/EP2951820B1 • ES2616434T3 • JP2016505902A/JP6148810B2 • KR20150108848A/KR101701081B1 • MX2015009745A/MX347410B • PT2951820T • **PL**2951820T3 • RU2015136467A/RU2618848C2 • SG11201505947XA • **WO2014118136A1** • US2015332698A1 • US2020227059A1 • **US**2019103121A1/US10622000B2	• **HK**1218461A1 • **TW**201434037A/**TW**I549120B

PATENTSCOPE AND DocDB families complement each other!

PATENTSCOPE: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2014118136

Espacenet: https://worldwide.espacenet.com/patent/search/family/050033499/publication/WO2014118136A1?q=WO2014118136

WIPO WORLD INTELLECTUAL PROPERTY ORGANIZATION

PATENTSCOPE vs. DOCDB Patent families – the case of almost identical but not quite…





PATENTSCOPE also shows national entries before publication!

PATENTSCOPE: https://patentscope.wipo.int/search/en/detail.jsf?docId=AU339282652&_cid=P21-KWAUG4-01982-11

Espacenet: https://worldwide.espacenet.com/patent/search/family/065802011/publication/WO2020182993A1?q=WO2020182993A1

PATENTSCOPE vs. DOCDB Patent families – the case of merging families…

EP2318495	LIGHT DUTY LIQUID CLEANING COMPOSITIONS AND METHODS OF MANUFACTURE AND USE THEREOF				17.06.2008	
Appl.No 08771272	Applicant COLGATE PALMOLIVE CO	Pub.Date 11.05.2011	Pub.Kind A1	Pub.Lang en	IC2	
US20110092407	LIGHT DUTY LIQUID CLEANING COMPOSITIONS AND METHODS OF MANUFACTURE AND USE THEREOF				17.06.2008	
Appl.No 12997622	Applicant Colgate-Palmolive Company	Pub.Date 21.04.2011	Pub.Kind A1	Pub.Lang	IC2	
CA2727307	LIGHT DUTY LIQUID CLEANING COMPOSITIONS AND METHODS OF MANUFACTURE AND USE THEREOF				17.06.2008	
Appl.No 2727307	Applicant COLGATE-PALMOLIVE COMPANY	Pub.Date 23.12.2009	Pub.Kind A1,C	Pub.Lang en	IC2	
AU2008358055	LIGHT DUTY LIQUID CLEANING COMPOSITIONS AND METHODS OF MANUFACTURE AND USE THEREOF				17.06.2008	
Appl.No 2008358055	Applicant Colgate-Palmolive Company	Pub.Date 16.12.2010	Pub.Kind B2	Pub.Lang	IC2	
MYPI 2010005951	LIGHT DUTY LIQUID CLEANING COMPOSITIONS AND METHODS OF MANUFACTURE AND USE THEREOF				17.06.2008	
Appl.No PI 2010005951	Applicant COLGATE PALMOLIVE COMPANY	Pub.Date 21.11.2013	Pub.Kind A	Pub.Lang	IC2	
WO/2009/154616	LIGHT DUTY LIQUID CLEANING COMPOSITIONS AND METHODS OF MANUFACTURE AND USE THEREOF				17.06.2008	
Appl.No PCT/US2008/067228	Applicant COLGATE-PALMOLIVE COMPANY	Pub.Date 23.12.2009	Pub.Kind A	Pub.Lang en	IC1	

In the same family both in PATENTSCOPE and DocDB

In the same family both in PATENTSCOPE and DocDB

PATENTSCOPE sometimes merges multiple DocDB families!

PATENTSCOPE; https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009154616&tab=FAMILY&_cid=P10-KNR6F3-57691-1

Espacenet: https://worldwide.espacenet.com/patent/search/family/040084270/publication/WO2009154616A1?q=WO2009154616

WIPO WORLD INTELLECTUAL PROPERTY ORGANIZATION

PATENTSCOPE vs. DOCDB Patent families – the case of merging families…



Not In the same family in DocDB

In the same family both in PATENTSCOPE and DocDB

PATENTSCOPE sometimes merges multiple DocDB families!

PATENTSCOPE: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009154616&tab=FAMILY&_cid=P10-KNR6F3-57691-1

Espacenet: https://worldwide.espacenet.com/patent/search/family/040084270/publication/WO2009154616A1?q=WO2009154616

WIPO WORLD INTELLECTUAL PROPERTY ORGANIZATION

Summary: things to remember

- The most fundamental difference between PATENTSCOPE and Espacenet is in the way they count coverage.
- The coverage of the two differs significantly and results in patent families which are rarely identical, but very often complementary!!!
- PATENTSCOPE's patent families strong point is the inclusion in the patent families members from authorities not present or poorly represented in Espacenet such as the Southeast Asian countries and India.



MARKUSH SEARCH

Access

- Released on September 13th 2021
- Available freely at https://patentscope.wipo.int
- Access only with a WIPO account
- Two ways to carry out a Markush Search



WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

Markush search: Using enumerated markush structures





WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

CHEM:(AQIXAKUUQRKLND-UHFFFAOYSA-N) OR ENUM:(AQIXAKUUQRKLND-UHFFFAOYSA-N)

28,070 results Offices all Languages all Stemming true Single Family Member false Include NPL false

Sort: Relevance Per page: 100 View: All+Image 1 / 281 Download Machine translation

1. **0560937** PHARMACEUTICAL COMPOSITIONS EP - 22.09.1993

Int.Class A61K 9/16 **Appl.No** 92903167 **Applicant** SMITHKLINE BEECHAM CORP **Inventor** MARSHALL KEITH

The present invention provides for a phased-release oral dosage form comprising a plurality of H_2? receptor antagonist pellets in a polymer matrix. Each phase, containing a plurality of pellets which may be optionally coated with a release delaying substance, may have different release rates, thereby providing release of the H_2? antagonist over an extended duration of time.

2. **0650353** PALATABLE PHARMACEUTICAL COMPOSITIONS EP - 03.05.1995

Int.Class A61K 9/00 **Appl.No** 93914418 **Applicant** SMITHKLINE BEECHAM CORP **Inventor** BHARDWAJ SANJAY

A pharmaceutical granular composition and method for taste masking bitter, unpleasant tasting drugs comprising a drug core and as a taste masking agent methacrylate ester copolymers. The method comprises coating the drug cores with separate layers of aqueous dispersions of the copolymers. Additionally, the coating composition may contain plasticizers and conventional excipients. The granules of the present invention can be used in the preparation of chewable tablets which have good palatability and bioavailability. Preferable copolymers are poly[ethylacrylate, methylmethacrylate] to which quaternary ammonium groups have been introduced to modify the permeability of the ester. The coating sytem of this invention releases the drug by diffusion and is influenced by drug solubility and media pH.

3. **0347767** DISPERSIBLE CIMETIDINE TABLETS EP - 27.12.1989

Int.Class A61K 9/20 **Appl.No** 89110951 **Applicant** LEK, TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV, D.D. **Inventor** KOVACIC, MATEJA

There are described novel dispersible cimetidine tablets containing 30 to 90 % by weight of one of the polymorphous modifications of cimetidine A, B or C, 5 to 55 % by weight of one or more disintegrationg agents, 0.05 to 5.0 % by weight of a surfactant, such as sodium lauryl sulphate together with other common adjuvants. The process for the manufacture of dispersible cimetidine tablets is effected on the basis of known methods by granulating the ingredients and by compressing the granulate to tablets. Dispersible tablets disintegrate when brought in contact with water at room temperature within less than 1 minute to yield a fine dispersion, which facilitates the oral application. Therefore such tablets are particularly suitable for certain groups of patients, especiallly for the aged and children. Dispersible tablets containing cimetidine excell by their improved rate of dissolution and good bioavailability



WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

Advantages

- Simplicity
- Response times
- Combination with other fields

ENUM:(AQIXAKUUQRKLND-UHFFFAOYSA-N) AND EN_AB:(gastric OR gastro)

75 results Offices all Languages all Stemming true Single Family Member false Include NPL false

Sort: Relevance Per page: 100 View: All+Image 1 / 1 Download Machine translation

1. **0108452** TREATMENT OF GASTRIC INFLAMMATORY DISEASE WITH CYTOPROTECTIVE PROSTAGLANDINS AND HISTAMINE-2 BLOCKING ANTI-SECRETORY AGENTS. EP - 16.05.1984

Int.Class A61K 31/415 Appl.No 83201551 Applicant PROCTER & GAMBLE Inventor WAGNER GREGORY STEVEN

Compositions comprising gastric cytoprotective prostaglandin or prostaglandin-like compounds and histamine-2 receptor blocking anti-secretory agents useful in the treatment and prophylaxis of gastric inflammatory conditions are disclosed. These compositions are effective in the treatment and prophylaxis of gastro-intestinal ulceration. They utilize levels of both prostaglandin and anti-secretory agents which are significantly lower than ordinarily required as the prostaglandin potentiates the effect of the anti-secretory agent, and minimizes the side effects which are frequently associated with the administration of prostaglandins. The method of treating and preventing gastric inflammatory diseases using these compositions is also disclosed.

2. **1209044** TREATMENT OF GASTRIC INFLAMMATORY DISEASE WITH CYTOPROTECTIVE PROSTAGLANDINS AND HISTAMIN-2 RECEPTOR BLOCKING ANTI-SECRETORY AGENTS CA - 05.08.1986

Int.Class A61K 31/557 Appl.No 440524 Applicant Inventor WAGNER, GREGORY S.

TREATMENT OF GASTRIC INFLAMMATORY DISEASE WITH CYTOPROTECTIVE PROSTAGLANDINS AND HISTAMINE-2 RECEPTOR BLOCKING ANTI-SECRETORY AGENTS ABSTRACT Compositions comprising gastric cytoprotective prostaglandin or prostaglandin-like compounds and histamine-2 receptor blocking anti-secretory agents useful in the treatment and prophylaxis of gastric inflammatory conditions are disclosed. These compositions are effective in the treatment and prophylaxis of gastro-intestinal ulceration. They utilize levels of both prostaglandin and anti-sec- retory agents which are significantly lower than ordinarily required as the prostaglandin potentiates the effect of the anti-secretory agent, and minimizes the side effects which are frequently associ- ated with the administration of prostaglandins. The method of treating and preventing gastric inflammatory diseases using these compositions is also disclosed.



3. **0814773** PECTIN LIQUID PHARMACEUTICAL COMPOSITIONS EP - 07.01.1998

Int.Class A61K 9/00 Appl.No 96908089 Applicant BOOTS CO PLC Inventor COX GILLIAN

The invention relates to a liquid composition for use in the prevention of gastric reflux, the composition comprising: a pectin gel raft-forming agent; a pectin, or a pharmaceutically acceptable salt thereof; a pharmaceutically acceptable metal ion component; one or more substances capable of producing a pharmaceutically acceptable gas at the physiological pH normally present in the stomach; the composition forming a gel raft in a gastric environment; in which the metal ion component is coated with a material to prevent the composition from forming a gel raft in a non-gastric environment. Preferably the composition further comprising one or more additional ingredients selected from: one or more antacid agents, one or more antibiotics, one or more anti-cholinergic agents, one or more anti-emetic agents, one or more cytoprotectants, one or more H¿2? receptor antagonists, one or more local anaesthetics, one or more proton pump inhibitors and any suitable and compatible mixtures thereof.

Disadvantages

- Limited recall
- Only exact compound

Markush search: By Matching Structures





WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION



WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION



WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION



WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

1. EP0446961 - STABILIZED PHARMACEUTICAL COMPOSITION AND ITS PRODUCTION

National Biblio. Data | Description | Claims | Patent Family | Compounds | Markush | Documents

PermaLink

Markush Nr.	Markush formula
9138-09401	

Enumerated compounds

Note: These structures have been created automatically. Please use the original Markush definition in the PDF version for legal matters

1 2 3 4 5 6 7 8 9 10

HBDKFZNDMVLSHM-UHFFFAOYSA-N



ZFUVBCOUKXFRIG-UHFFFAOYSA-N



ZFUVBCOUKXFRIG-UHFFFAOYSA-N



BQSRNAUDMPQYKZ-UHFFFAOYSA-N



SOMRZJSTDCVDES-UHFFFAOYSA-N



SOMRZJSTDCVDES-UHFFFAOYSA-N



NJJRWERALDFUMA-UHFFFAOYSA-N



LEPJWVYZVKEIPB-UHFFFAOYSA-N



LEPJWVYZVKEIPB-UHFFFAOYSA-N



MSVPDUIRKKWSDW-UHFFFAOYSA-N



YNRXQBPXUVQHBZ-UHFFFAOYSA-N



YNRXQBPXUVQHBZ-UHFFFAOYSA-N



Advantages

- Recall
- Search scope
- Search options

Disadvantages

- Long response times
- Complex
- No repeating group

Repeating groups

- all repeating groups in the indexed Markush structures are standardized to one repetition

Manual edition

Variable groups



Resources/Information

- PATENTSCOPE

  https://patentscope.wipo.int
- PATENTSCOPE Team

  patentscope@wipo.int

  patentscope-data@wipo.int
- PATENTSCOPE Webinars

  https://www.wipo.int/meetings/en/topic.jsp?group_id=312

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION